Abbott Reviews 16 More information here .1 Percent Sales Growth in Fourth Quarter Abbott today announced financial results for the fourth quarter ended Dec. 31, 2007. Worldwide product sales in the fourth one fourth elevated 16.1 % to $7.2 billion, including a good 4.5 % aftereffect of exchange rates. For the full-year 2007, worldwide sales improved 15.3 % to $25.9 billion, including a favorable 3.2 % effect of exchange rates. U.S. Pharmaceutical sales increased 16.6 % and international pharmaceutical product sales increased 21.3 %, driven by double-digit growth in HUMIRA, Kaletra and TriCor, and including $179 million of Niaspan sales.
Worldwide sales elevated 14.6 % to $7.7 billion, including a good 4.1 % aftereffect of exchange rates. Diluted earnings per share, excluding specified products, were $0.81, reflecting 11.0 % growth, at the high end of Abbott’s previously issued assistance selection of $0.79 to $0.81. Excluding an unfavorable $0.03 per share effect from U.S. Health care reform, first one fourth ongoing earnings per talk about could have been $0.84, up 15.1 %. Diluted earnings per talk about under Generally Approved Accounting Concepts were $0.64. Product sales were reduced by around $60 million as a result of higher Medicaid rebates under U.S. Health care reform. Excluding this effect, sales would have improved 15.5 %. Worldwide pharmaceutical sales improved 12.9 %, including a good 4.4 % effect of exchange rates, powered by double-digit growth for HUMIRA and Abbott’s lipid administration franchise.